781626-14-0

Basic information

• Product Name: 1-chloro-1-[1-(4-methoxyphenyl)vinyl]-1-silacyclohexane
• Synonyms: 1-chloro-1-[1-(4-methoxyphenyl)vinyl]-1-silacyclohexane
• CAS NO: 781626-14-0
• Molecular Weight: 266.843
• Mol File: 781626-14-0.mol

Chemical Properties

• CAS DataBase Reference: 1-chloro-1-[1-(4-methoxyphenyl)vinyl]-1-silacyclohexane(CAS DataBase Reference)
• NIST Chemistry Reference: 1-chloro-1-[1-(4-methoxyphenyl)vinyl]-1-silacyclohexane(781626-14-0)
• EPA Substance Registry System: 1-chloro-1-[1-(4-methoxyphenyl)vinyl]-1-silacyclohexane(781626-14-0)

Safety Data

• Hazardous Substances Data: 781626-14-0(Hazardous Substances Data)

Upstream product

• 781626-13-9 1-[1-(4-methoxyphenyl)vinyl]-1-(2,4,6-trimethoxyphenyl)-1-silacyclohexane 
• 2406-34-0 1,1-dichloro-1-silacyclohexane 
• 781626-12-8 1-methoxy-1-(2,4,6-trimethoxyphenyl)-1-silacyclohexane 

Downstream Products

• 521059-16-5 {1-[2-dimethylamino-1-(4-methoxy-phenyl)-ethyl]-silinan-1-yl}-dimethyl-amine 
• 521059-17-6 rac-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1-ol 

Relevant articles and documents

(R)-Sila-venlafaxine: A selective noradrenaline reuptake inhibitor for the treatment of emesis

Sila-substitution of drugs (the carbon/silicon switch) is a concept that is being successfully used for the development of new chemical entities. The (R)-sila-analogue of the antidepressant venlafaxine is devoid of the serotonin reuptake inhibition observ

1-(2-AMINO-1-PHENYL-ETHYL) 1- SILACYCLOHEXAN-1- OL DERIVATIVES AND USE THEREOF IN THE PREPARATION OF A MEDICAMENT

A compound selected from: (RS)-1-[2-methylamino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1-ol; (R)-1-[2-methylamino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1-ol; (S)-1-[2-methylamino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1-ol; (RS)-1-[2-amino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1-ol; (R)-1-[2-amino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1-ol (S)-1-[2-amino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1-ol; (RS)-1-[2-dimethylamino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (R)-1-[2-dimethylamino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (S)-1-[2-dimethylamino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (RS)- 1-[2-amino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (R)-1-[2-amino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (S)-1-[2-amino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (RS)- 1-[2-methylamino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (R)-1-[2-methylamino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (S)-1-[2-methylamino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (RS)-1-[2-dimethyl amino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1,4-diol; (R)-1-[2-dimethylamino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-l,4-diol; and (S)-1-[2-dimethylamino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1,4-diol; or a pharmaceutically acceptable salt thereof or a prodrug form that is hydrolysable to a compound as defined above.